Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Long-Term Debt Repayments: 2020-2022

Historic Long-Term Debt Repayments for Cidara Therapeutics (CDTX) over the last 3 years, with Dec 2022 value amounting to $2.6 million.

  • Cidara Therapeutics' Long-Term Debt Repayments fell 66.61% to $371,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2022, which is 41.65% down from last year.
  • As of FY2022, Cidara Therapeutics' Long-Term Debt Repayments stood at $2.6 million, which was down 41.65% from $4.4 million recorded in FY2021.
  • In the past 5 years, Cidara Therapeutics' Long-Term Debt Repayments registered a high of $4.4 million during FY2021, and its lowest value of $2.6 million during FY2022.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $3.0 million (2020), whereas its average is $3.3 million.
  • In the last 5 years, Cidara Therapeutics' Long-Term Debt Repayments soared by 49.98% in 2021 and then crashed by 41.65% in 2022.
  • Yearly analysis of 3 years shows Cidara Therapeutics' Long-Term Debt Repayments stood at $3.0 million in 2020, then surged by 49.98% to $4.4 million in 2021, then tumbled by 41.65% to $2.6 million in 2022.